Adcendo Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
60
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$74.1M
- Investors
-
21
Adcendo General Information
Description
Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. The company's conjugates are directed at a target receptor, which is an approach that helps targeted therapy in several cancer forms where expression of the target is unregulated, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, enabling doctors to treat patients with diseases such as carcinomas, breast, colon, pancreatic, prostate, ovarian, and renal cancers.
Contact Information
Website
www.adcendo.comCorporate Office
- C/o Symbion Frederiksberg
- Nordre Fasanvej 215
- 2000 Frederiksberg
- Denmark
Corporate Office
- C/o Symbion Frederiksberg
- Nordre Fasanvej 215
- 2000 Frederiksberg
- Denmark
Adcendo Timeline
Adcendo Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series C) | 14-Apr-2026 | $74.1M | Completed | Pre-Clinical Trials | ||
| 6. Later Stage VC (Series B) | 29-May-2024 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series A) | 04-Apr-2023 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 29-Aug-2019 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 28-Nov-2017 | Completed | Startup | |||
| 2. Grant | 03-Nov-2017 | $631K | Completed | Startup | ||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
Adcendo Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 531,920 | $211.24 | $211.24 | 1x | $211.24 | 36.71% | ||
| Ordinary | 10,000 | $5.42 | $5.42 | 1x | $5.42 | 0.69% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Adcendo Comparisons
Industry
Financing
Details
Adcendo Competitors (5)
One of Adcendo’s 5 competitors is MonTa BioSciences, a Venture Capital-Backed company based in Lyngby, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MonTa BioSciences | Venture Capital-Backed | Lyngby, Denmark | ||||
| Evaxion | Formerly VC-backed | Hoersholm, Denmark | ||||
| Genmab | Formerly VC-backed | Valby, Denmark | ||||
| Araris | Formerly VC-backed | Zurich, Switzerland | ||||
| Ambrx | Formerly PE-Backed | San Diego, CA |
Adcendo Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adcendo Patents
Adcendo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025244755-A1 | Anti-gpc1 antibodies and uses thereof | Pending | 27-Mar-2024 | ||
| WO-2025202359-A1 | Anti-gpc1 antibodies and uses thereof | Pending | 27-Mar-2024 | ||
| WO-2025202361-A1 | Anti-gpc1 antibodies and uses thereof | Pending | 27-Mar-2024 | ||
| AU-2023417911-A1 | Antibody-drug conjugates targeting uparap comprising exatecan derivatives | Pending | 28-Dec-2022 | ||
| EP-4642487-A1 | Antibody-drug conjugates targeting uparap comprising exatecan derivatives | Pending | 28-Dec-2022 | A61K47/68037 |
Adcendo Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adcendo Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| Denmark's Export and Investment Fund | Venture Capital | Minority | ||
| Jeito | Growth/Expansion | Minority | ||
| Vida Ventures (Los Angeles) | Venture Capital | Minority | ||
| Logos Capital | Hedge Fund | Minority |
Adcendo FAQs
-
When was Adcendo founded?
Adcendo was founded in 2017.
-
Where is Adcendo headquartered?
Adcendo is headquartered in Frederiksberg, Denmark.
-
What is the size of Adcendo?
Adcendo has 60 total employees.
-
What industry is Adcendo in?
Adcendo’s primary industry is Drug Discovery.
-
Is Adcendo a private or public company?
Adcendo is a Private company.
-
What is the current valuation of Adcendo?
The current valuation of Adcendo is .
-
What is Adcendo’s current revenue?
The current revenue for Adcendo is .
-
How much funding has Adcendo raised over time?
Adcendo has raised $313M.
-
Who are Adcendo’s investors?
Bpifrance, Denmark's Export and Investment Fund, Jeito, Vida Ventures (Los Angeles), and Logos Capital are 5 of 21 investors who have invested in Adcendo.
-
Who are Adcendo’s competitors?
MonTa BioSciences, Evaxion, Genmab, Araris, and Ambrx are competitors of Adcendo.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
